Posted inBiotechnology
Contineum’s J&J-partnered MS drug fails to improve vision in phase 2
Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with…
Posted inMedical Technology
GE HealthCare to acquire imaging software provider Intelerad for $2.3B
GE HealthCare plans to pay $2.3 billion in cash to acquire imaging software developer Intelerad, toward the goal of building…
Posted inBiotechnology
Chutes & Ladders—Gilead abruptly parts ways with general counsel
Editor's note: The Fierce team will be out of office next Friday for the Thanksgiving holiday. The next edition of…
Posted inBiotechnology
Moderna’s reshaping rolls on with 3 more pipeline purges
Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including…
Posted inMedical Technology
The Cooper Companies under activist pressure to split—in different ways
The Cooper Companies have recently faced pressure from activist investors on two fronts, with pushes to split up their businesses…
Posted inBiotechnology
Pfizer’s mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential…
Posted inMedical Technology
Abbott dives into cancer diagnostics with $23B buyout of Exact Sciences
In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for…
Posted inBiotechnology
Ensoma halves workforce after transitioning genetic medicine to the clinic
Genetic medicine outfit Ensoma is halving its workforce, with most of the impacted roles related to platform research functions. The…
Posted inBiotechnology
Applied Tx lays off 46% of workforce as rare disease drug approval looks out of reach
Facing skepticism from analysts about whether it has the resources to take its rare disease drug to market, Applied Therapeutics…
Posted inBiotechnology
Novartis CEO paid top dollar for Avidity to become a ‘leader in neuromuscular diseases’
Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but, as the company’s CEO sees…